Alphatec Holdings AI Stock Analysis
Want to see ATEC full AI Analyst Report?
Alphatec Holdings (ATEC) AI Stock Analysis
Alphatec Holdings
(NASDAQ:ATEC)
ATEC scores in the high-40s primarily due to mixed financial performance: improving cash flow and a healthier TTM balance sheet are offset by a TTM revenue pullback and ongoing net losses. Technicals are a major drag given the strong downtrend versus key moving averages and bearish momentum readings. The earnings call adds modest support via continued EBITDA/margin expansion and demand indicators, but guidance reductions and execution headwinds cap the score, while valuation signals are constrained by a negative P/E and no dividend yield data.
Alphatec Holdings (ATEC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.08B
- Dividend Yield
- ―
- Average Volume (3M)
- 3.31M
- Price to Earnings (P/E)
- -12.3
- Beta (1Y)
- 0.62
- Revenue Growth
- 15.34%
- EPS Growth
- 46.31%
- Country
- US
- Employees
- 913
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Alphatec Holdings Business Overview & Revenue Model
Company Description
Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX Sys...
How the Company Makes Money
Alphatec primarily makes money by selling spine-surgery products used in surgical procedures. The core revenue stream is product revenue generated from the sale of spinal implants (e.g., fixation systems, interbody devices and related implants), the...
Alphatec Holdings Earnings Call Summary
The call presented strong underlying operating momentum, including 13% revenue growth, 20% procedural volume growth, approximately 25% surgeon adoption growth, significant EBITDA and margin expansion, positive free cash flow, and continued progress in Valence and EOS Insight. However, the quarter was described as frustrating because revenue missed expectations, biologics revenue declined, revenue per case fell 5%, thoracolumbar volumes were soft, EOS revenue was flat year-over-year, international supply issues affected adoption, and full-year revenue and free cash flow guidance were reduced. The positive operating and strategic developments were balanced by meaningful execution and market challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company lowered full year 2026 total company revenue expectations to approximately $862 million, representing growth of roughly 13%, including surgical revenue of approximately $789 million, representing growth of approximately 15%, and EOS revenue of approximately $73 million; the outlook includes high-teens surgical case volume growth, a 3% decline in revenue per case, $102 million of year-over-year surgical dollar growth, 17% surgical hardware revenue growth and flat biologics revenue contribution year-over-year, with a temporary international supply constraint expected to impact international sales by about $3 million for the year and resolve as we enter 2027. Adjusted EBITDA is expected to be approximately $137 million, or a 16% margin, representing growth of approximately 47% year-over-year, and free cash flow is expected to be $10 million, implying approximately $15 million in the fourth quarter; the fourth-quarter guide implies an 18% EBITDA ratio, about $12 million associated with surgical volume and $4 million with EOS, with the surgical reduction approximately evenly split between lower biologics expectation and lower procedural volumes, or about $6 million and $6 million.
Alphatec Holdings Financial Statement Overview
Summary
Financials are improving but still mixed. Income statement quality is pressured by a notable TTM revenue pullback and continued net losses despite narrowing losses and slightly positive TTM EBITDA. The balance sheet looks healthier in TTM with very low debt-to-equity (~0.04) and meaningful positive equity, but returns remain negative. Cash flow has turned positive (operating cash flow and small positive free cash flow), though still modest relative to losses and inconsistent versus prior years’ burn.
Income Statement
42NeutralBalance Sheet
63PositiveCash Flow
56Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 839.72M | 764.15M | 611.56M | 482.26M | 350.87M | 243.21M |
| Gross Profit | 560.07M | 531.89M | 424.26M | 310.20M | 233.06M | 157.76M |
| EBITDA | 32.32M | -39.70M | -53.87M | -110.59M | -102.58M | -106.88M |
| Net Income | -86.89M | -143.36M | -162.12M | -186.64M | -151.29M | -143.03M |
Balance Sheet | ||||||
| Total Assets | 796.75M | 791.21M | 775.71M | 805.21M | 520.97M | 572.05M |
| Cash, Cash Equivalents and Short-Term Investments | 79.94M | 160.81M | 138.84M | 220.97M | 84.70M | 187.25M |
| Total Debt | 593.95M | 619.95M | 609.94M | 541.68M | 395.86M | 355.43M |
| Total Liabilities | 775.44M | 755.18M | 766.28M | 703.49M | 555.63M | 492.63M |
| Stockholders Equity | 21.30M | 36.03M | 9.43M | 101.72M | -34.67M | 79.42M |
Cash Flow | ||||||
| Free Cash Flow | 4.92M | 2.78M | -137.79M | -165.46M | -133.41M | -141.86M |
| Operating Cash Flow | 61.34M | 45.23M | -44.65M | -78.48M | -75.13M | -73.32M |
| Investing Cash Flow | -80.16M | -53.41M | -93.14M | -141.97M | -58.28M | -157.76M |
| Financing Cash Flow | -56.78M | 30.02M | 56.21M | 356.92M | 31.23M | 311.97M |
Alphatec Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATEC, the sentiment is Negative. The current price of 6.94 is below the 20-day moving average (MA) of 8.64, below the 50-day MA of 9.65, and below the 200-day MA of 10.04, indicating a bearish trend. The MACD of -0.91 indicates Positive momentum. The RSI at 34.49 is Neutral, neither overbought nor oversold. The STOCH value of 10.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATEC.
Alphatec Holdings Risk Analysis
Alphatec Holdings disclosed 78 risk factors in its most recent earnings report. Alphatec Holdings reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAlphatec Holdings Peers Comparison
Overall Rating
MDT81Outperform
SYK75Outperform
GMED73Outperform
ZBH69Neutral
ATEC49Neutral
OFIX44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $130.88B | 25.13 | 10.60% | 2.80% | 9.77% | 12.28% | |
| 75Outperform | $120.88B | 33.61 | 15.61% | 1.11% | 7.87% | 22.82% | |
| 73Outperform | $9.27B | 16.99 | 11.82% | ― | 13.35% | 32.22% | |
| 69Neutral | $19.32B | 25.92 | 6.05% | 0.94% | 6.98% | -2.22% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $1.08B | -12.34 | -547.17% | ― | 15.34% | 46.31% | |
| 44Neutral | $271.87M | -5.99 | -10.32% | ― | 2.12% | 63.59% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ATEC | Alphatec | 6.94 | -12.68 | -64.63% | |
| MDT | Medtronic | 102.32 | 5.20 | 5.35% | |
| OFIX | Orthofix Medical Inc. | 6.67 | -7.79 | -53.87% | |
| SYK | Stryker Corp | 317.54 | -42.70 | -11.85% | |
| ZBH | Zimmer Biomet Holdings | 102.09 | 13.59 | 15.35% | |
| GMED | Globus Medical | 69.99 | -13.83 | -16.50% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026
